Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/02/24
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powderGlobeNewsWire • 04/01/24
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/13/24
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/13/24
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024GlobeNewsWire • 03/06/24
United Therapeutics starts litigation with FDA for allowing Liquidia's drug applicationReuters • 02/21/24
Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share PricesSeeking Alpha • 02/13/24
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual CongressGlobeNewsWire • 01/30/24
Wall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 71.41%: Read This Before Placing a BetZacks Investment Research • 01/29/24
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powderGlobeNewsWire • 01/25/24
Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 29.94%: Here's is How to TradeZacks Investment Research • 01/10/24
What Makes Liquidia Technologies, Inc. (LQDA) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 01/09/24
Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files CounterclaimsGlobeNewsWire • 01/08/24
Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/02/24
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)GlobeNewsWire • 12/20/23
Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/07/23